NEW
YORK, April 26, 2023 /PRNewswire/ -- Elevation
Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company
focused on the discovery and development of selective cancer
therapies to treat patients across a range of solid tumors with
significant unmet medical needs, today announced that an abstract
featuring SYSA1801 (EO-3021) Phase 1 clinical data has been
selected for a poster presentation and poster discussion at the
upcoming American Society of Clinical Oncology (ASCO) 2023 Annual
Meeting, being held June 2-6, 2023 in
Chicago, IL. The ongoing Phase 1
dose escalation and dose expansion study is evaluating SYSA1801 in
patients with Claudin 18.2-positive advanced solid tumors and is
being conducted in China by
Elevation Oncology's partner, CSPC Pharmaceutical Group Limited
(CSPC; HKEX: 01093). Elevation Oncology remains on track to
initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 in
the second half of 2023.
"Claudin 18.2 is a clinically validated oncology target that is
expressed in several high unmet need cancers, including gastric,
esophageal and pancreatic, among others, and there are currently no
approved targeted therapies for Claudin 18.2-expressing tumors,"
said Valerie Malyvanh Jansen, M.D.,
Ph.D., Chief Medical Officer of Elevation Oncology. "We believe
EO-3021 has the potential to address unmet needs for patients with
Claudin 18.2-expressing tumors, and we look forward to our partner,
CSPC, presenting at ASCO 2023."
ASCO 2023 Presentation Details:
Title: First-in-human dose escalation and expansion study
of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in
patients with resistant/refractory solid tumors.
Presenter: Dr. Yakun Wang
Session Type: Poster Discussion Session
Session Title: Molecularly Targeted Agents and Tumor
Biology
Poster Session Date and Time: Saturday, June 3, 2023,
8:00 a.m. – 11:00 a.m. ET
Poster Discussion Date and Time: Saturday, June 3, 2023, at 1:15 p.m. ET
Abstract Number: 3016
Poster Number: 214
About EO-3021
EO-3021 (also known as SYSA1801) is a differentiated,
clinical-stage antibody drug conjugate (ADC) comprised of an
immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets
Claudin 18.2 and is site-specifically conjugated to the monomethyl
auristatin E (MMAE) payload via a cleavable linker with a
drug-to-antibody ratio (DAR) of 2. Claudin 18.2 is a specific
isoform of Claudin 18 that is only expressed in gastric epithelial
cells. During malignant transformation in many solid tumors, the
tight junctions may become disrupted, exposing Claudin 18.2 and
allowing them to be accessible by Claudin 18.2 targeting agents. An
Investigational New Drug application for EO-3021 has been cleared
by the U.S. Food and Drug Administration.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are rethinking drug development by seeking
out innovative, selective cancer therapies that can be matched to a
patient's unique tumor characteristics. Our lead candidate,
EO-3021, is a potential best-in-class antibody drug conjugate (ADC)
designed to target Claudin 18.2, a clinically validated molecular
target. EO-3021 selectively delivers a cytotoxic payload directly
to cancer cells expressing Claudin 18.2. We are working to rapidly
advance EO-3021 into the clinic in the US across a range of solid
tumor indications, as well as exploring other opportunities through
new or existing partnerships and business development opportunities
to expand our novel oncology pipeline. For more information, visit
www.ElevationOncology.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated clinical development activities, expected
timing of announcements of clinical results, potential benefits of
Elevation Oncology's product candidates, potential market
opportunities for Elevation Oncology's product candidates, and the
ability of Elevation Oncology's product candidates to treat their
targeted indications. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These forward-looking statements may be accompanied by
such words as "aim," "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "goal," "intend," "may," "might," "plan,"
"potential," "possible," "will," "would," and other words and terms
of similar meaning. Although Elevation Oncology believes that the
expectations reflected in such forward-looking statements are
reasonable, Elevation Oncology cannot guarantee future events,
results, actions, levels of activity, performance or achievements,
and the timing and results of biotechnology development and
potential regulatory approval are inherently uncertain.
Forward-looking statements are subject to risks and uncertainties
that may cause Elevation Oncology's actual activities or results to
differ significantly from those expressed in any forward-looking
statement, including risks and uncertainties related to Elevation
Oncology's ability to advance its product candidates, the timing
and results of preclinical studies and clinical trials, approvals
and commercialization of product candidates, the receipt and timing
of potential regulatory designations, the impact of the COVID-19
pandemic on Elevation Oncology's business, Elevation Oncology's
ability to fund development activities and achieve development
goals, Elevation Oncology's ability to protect intellectual
property, Elevation Oncology's ability to establish and maintain
collaborations with third parties, and other risks and
uncertainties described under the heading "Risk Factors" in
documents Elevation Oncology files from time to time with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release, and
Elevation Oncology undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-highlights-clinical-data-for-sysa1801-eo-3021-to-be-presented-by-partner-cspc-pharmaceutical-group-limited-at-asco-2023-301808646.html
SOURCE Elevation Oncology